Skip to main content
GNPX logo

GNPX · Genprex, Inc.

Track GNPX — free
$3.55 -0.16 (-4.31%)
Market Cap
$3.01M
Shares
819,709

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.71 Open$3.73 Day$3.63–3.84 Since split$3.61–8.41 Avg vol 30d329K Short int63K · 7.6% float · 1.0d Short vol19% DataJul 2026–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Jul 16, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jul 16, 2026.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.70
Technical
price trend
Sell
50 / 200-day cross No cross
RSI (14) 29
oversold
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+4% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.64% of float · ▲ +69.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Squeeze score 56
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 111%
annualized · 1-yr
Max drawdown −57%
past year
ATR 14.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 3 · 0
50 / 200-day cross
No cross Neutral
RSI (14)
29 Neutral
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+4% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.64% of float · ▲ +69.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Price context
position in its range since split · 2026-07-16
Range low $4 Now $4 · 2% Range high $8

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GNPX
Genprex, Inc.
this stock
$3.01M 7.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
$137.30B +20.1% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$81.77B +3.5% +20.8% 19.7 2.3%
ARGX
Argenx SE
$64.16B +22.7% 1.9%
CSLLY
Csl Ltd
$59.51B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
1.7%
Net QoQ
+9.4K sh
Top holder
VANGUARD FIDUCIARY TRUST…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
62.6K
Days to cover
1.0d
Change
+25.7K sh
View
Short Volume
Short vol %
19%
As of
Aug 31, 2026
Short Total
View
Fails to Deliver
FTD shares
565
Value
$2.7K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
54.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Tim Moore
Amount
$1.0K–$15.0K
Traded
Feb 5, 2026
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-16.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
23
View

Performance

Raw-price comparisons begin at the captured split on Jul 16, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
GNPX -7.7% -21.9% -38.1%
SPY +0.5% +1.2% +13.3% +2.7% +12.5%
vs SPY -8.2% -23.1% -40.7%
Key facts CIK 1595248 CUSIP 372446401 13F (30d) 24 filings 24 filers Visit website Investor relations